The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price gain of 484.41% this year. Over the last six months, there has been a weaker performance of 126.81%. The price of VRNA fallen by 16.36% during the last 30 days period. For the last 5-days stocks have improved 14.90%.
The present stock price for Verona Pharma Plc ADR (VRNA) is $104.79. In the last trading session, the stock made a considerable jump, reaching $170.0 after an opening price of $104.8. The stock briefly fell to $90.0 before ending the session at $104.83.
The market performance of Verona Pharma Plc ADR’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $104.99 on 07/10/25, while the lowest value for the same duration was $18.51 on 08/05/24.
52-week price history of VRNA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Verona Pharma Plc ADR’s current trading price is -0.20% away from its 52-week high, while its distance from the 52-week low is 466.10%. The stock’s price range during this period has varied between$18.51 and $104.99. The Verona Pharma Plc ADR’s shares, which operate in the Healthcare, saw a trading volume of around 8.14 million for the day, a figure considerably higher than their average daily volume of 2.75 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Verona Pharma Plc ADR (VRNA) has experienced a quarterly rise of 94.30% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 8.92B and boasts a workforce of 209 employees.
Verona Pharma Plc ADR: Analysts’ Ratings Unveiled
As of right now, 8 analysts are rating Verona Pharma Plc ADR as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 73.51, with a change in price of +40.53. Similarly, Verona Pharma Plc ADR recorded 2,318,351 in trading volume during the last 100 days, posting a change of +63.08%.
VRNA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for VRNA stands at 1.08. Similarly, the long-term debt-to-equity ratio is also 1.07.
VRNA Stock Stochastic Average
Verona Pharma Plc ADR’s raw stochastic average for the past 50 days is presently 99.53%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 98.86%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 99.07% and 90.88%, respectively.
